These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22911090)

  • 1. Molecular characterization of quinolone-insensitive Streptococcus pneumoniae isolates from Japanese patients.
    Araki N; Yanagihara K; Matsukawa Y; Harada Y; Migiyama Y; Nagaoka K; Yamada K; Morinaga Y; Hasegawa H; Kohno S; Kamihira S
    J Infect Chemother; 2013 Apr; 19(2):356-9. PubMed ID: 22911090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
    Sunagawa S; Fujita J; Higa F; Tateyama M; Haranaga S; Nakasone I; Yamane N; Uno T
    J Antibiot (Tokyo); 2011 Aug; 64(8):539-45. PubMed ID: 21587266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Yokota S; Ohkoshi Y; Fujii N
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):76-80. PubMed ID: 19679241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Nakai H; Sato T; Uno T; Furukawa E; Kawamura M; Takahashi H; Watanabe A; Fujimura S
    J Infect Chemother; 2018 Feb; 24(2):83-87. PubMed ID: 29290527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.
    Grohs P; Houssaye S; Aubert A; Gutmann L; Varon E
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3542-7. PubMed ID: 14576115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of quinolone resistance-determining regions and their correlation with serotypes and genotypes among Streptococcus pneumoniae isolates in Japan.
    Osawa M; Ito Y; Ishida T; Imai S; Ichiyama S; Mishima M;
    Eur J Clin Microbiol Infect Dis; 2010 Feb; 29(2):245-8. PubMed ID: 19936985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
    Avrain L; Garvey M; Mesaros N; Glupczynski Y; Mingeot-Leclercq MP; Piddock LJ; Tulkens PM; Vanhoof R; Van Bambeke F
    J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of genes encoding the quinolone resistance determining regions of Malaysian Streptococcus pneumoniae strains.
    Kumari N; Subramaniam G; Navaratnam P; Sekaran SD
    Indian J Med Microbiol; 2008; 26(2):148-50. PubMed ID: 18445951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
    Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.
    Zhanel GG; Walkty A; Nichol K; Smith H; Noreddin A; Hoban DJ
    Diagn Microbiol Infect Dis; 2003 Jan; 45(1):63-7. PubMed ID: 12573552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
    Browne FA; Bozdogan B; Clark C; Kelly LM; Ednie L; Kosowska K; Dewasse B; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bactericidal activity of sitafloxacin and other new quinolones against antimicrobial resistant Streptococcus pneumoniae].
    Kobayashi I; Kanayama A; Hasegawa M; Kaneko A
    Jpn J Antibiot; 2013 Feb; 66(1):25-35. PubMed ID: 23777014
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Murata M; Kosai K; Yamauchi S; Sasaki D; Kaku N; Uno N; Morinaga Y; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.